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Abstract 
Background 
Women at increased risk of breast cancer are eligible for chemoprevention. Healthy lifestyles are 
potentially important for these women in terms of improving the efficacy, minimising side effects of 
chemopreventative agents and reducing risk of breast cancer and other lifestyle related conditions.  
Methods 
We examined lifestyle risk factors and health measures in 136 premenopausal women taking 
tamoxifen for prevention of breast cancer (Tam-Prev study) compared to an age-matched female 
population from the Health Survey for England 2012. 
Results 
The Tam-Prev population had high rates of overweight and obesity (59.2%) and low adherence to 
physical activity recommendations (30.6%) which were comparable to the general population 
(respectively 55.2% and 35.1%). Fewer Tam-Prev participants were current smokers (10.5% vs. 18.2%, 
p=0.032), but more exceeded UK alcohol recommendations (45.0% vs. 18.7%, p<0.001). Tam-Prev 
participants had suboptimal diets; proportions not meeting fibre, saturated fat and non-milk extrinsic 
sugar recommendations were 87.8%, 64.9% and 21.4% respectively. Many Tam-Prev participants had 
markers of cardiovascular disease and the metabolic syndrome. Health behaviours did not change 
during the first year on tamoxifen.  
Conclusion 
Tam-Prev participants had a high prevalence of unhealthy lifestyle behaviours and health measures, 
similar to an age-matched English cohort. Improving these measures in women at increased breast 
cancer risk could significantly decrease rates of breast cancer and other non-communicable diseases. 
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Background 
Breast cancer (BC) is the most common cancer in the UK with 55,122 diagnoses in 20151. Expert 
reports estimate maintaining a healthy weight, limiting alcohol, and being physically active could 
prevent 19-38% of BC in the UK2,3. Further reductions would be achieved through not smoking4,5.  
 
Tamoxifen is one of three drugs licenced for chemoprevention of BC in women at increased risk of BC 
in the UK. Tamoxifen reduces BC risk by 40% but carries an increased risk of venous thromboembolism 
and postmenopausal endometrial cancer, as well as vasomotor side effects.  
 
Although evidence is mixed, there are suggestions from the adjuvant6 and prevention7 settings that 
chemopreventative medications are less effective in overweight women, and carry more side effects8–
10. Furthermore since the majority of women taking chemoprevention will not develop BC11, they need 
to attend to their risk of other lifestyle-related diseases, for example cardiovascular disease (CVD).  
 
There are no published data on the lifestyle behaviours of women taking BC chemoprevention. This 
paper describes the lifestyle behaviours and health measures of women on the Tamoxifen Prevention 
Study12 (Tam-Prev, ISRCTN 53844391), and changes during a year of chemoprevention.  
 
Materials and Methods 
Participants 
The Tam-Prev recruited 136 premenopausal women at increased risk of BC between 2011-2012 to 
establish uptake of tamoxifen for BC prevention, and to determine who is most likely to benefit.  
 
The Tam-Prev study has been described previously12. Women were eligible if they were at moderately 
high or high risk of BC (≥17% lifetime risk)13, attending a regional Family History Clinic (FHC), aged 33-
46 years, premenopausal and not on hormonal contraception. From 1279 eligible women invited, 136 
agreed to take tamoxifen for one year (10.6% uptake).  
 
Procedures 
Women were asked to take tamoxifen (20mg/d) and were reviewed at eight weeks and one year. No 
lifestyle advice was given. All participants had previously been given a leaflet on BC prevention upon 
joining the FHC which included advice to control weight, limit alcohol and increase physical activity 
(PA). 
 
Assessments at baseline (before commencing tamoxifen) and one year included weight and body fat 
determined by multi-frequency bioelectrical impedance (MC-180MA; Tanita Europe, Amsterdam, The 
Netherlands), waist circumference, fasting lipids, insulin and glucose taken using standardised 
methods described previously14. Self-reported dietary intake was assessed at baseline and one year 
from seven day food diaries checked for completeness with the respondent and analysed using WISP 
v3.3 (Tinuviel Software, Anglesey, UK) for mean daily saturated fatty acids, fibre (Association of Official 
Analytical Chemists [AOAC] method), non-milk extrinsic sugars (NMES: total of sugars added during 
manufacturing or before consumption, sugars in honey, syrups and unsweetened fruit juices, and 50% 
of sugars from dried, stewed or canned fruit) and alcohol. Self-reported PA in the past seven days was 
assessed using the International Physical Activity Questionnaire (IPAQ) short version at the same time 
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points15 and was used to calculate Metabolic Equivalent of Task (MET). Walking at 3.0 miles per hour 
is a 3.3 MET activity, and an hour of brisk walking equates to 3.3 x 60 = 198 MET-minutes. 
 
Insulin was measured by chemiluminescent microparticle immunoassay (ARCHITECT i2000, Abbott, 
Illinois, USA). Glucose was measured by hexokinase/glucose-6-phosphate inter-assay dehydrogenase 
method and colorimetric enzyme reactions were used to measure total cholesterol, triglycerides and 
HDL cholesterol (all ARCHITECT c1600, Abbott, Illinois, USA). Levels were measured 
spectrophotometrically by an automated Olympus AU600 analyser (Olympus, Rungis, France). LDL 
cholesterol was calculated using the formula of Friedewald et al16. Fasting insulin and glucose were 
combined to calculate the insulin resistance index using the homeostasis model assessment (HOMA)17.  
 
Statistics  
We compared data from the Tam-Prev population (age, deprivation level, BMI, waist circumference, 
total and HDL cholesterol, smoking, alcohol and PA habits) to a population of 1072 English women 
aged 33-46 years in the 2012 Health Survey for England (HSE)18. Indices of Deprivation 2007 Layer 
Super Output Area Scores were identified from participant postcodes via Geoconvert19. There were 
some methodological differences between the two data sets; waist circumferences in Tam-Prev were 
measured across the umbilicus whereas HSE used the midpoint between the lower rib and the upper 
margin of the iliac crest. PA data were collected in Tam-Prev by the IPAQ short version covering the 
previous seven days, and in HSE by a longer set of questions covering the previous four weeks18. We 
assessed changes in weight, BMI, body composition, waist circumference and dietary intakes at one 
year in the Tam-Prev cohort. Changes in lipids, glucose or HOMA were not assessed as these can be 
altered by tamoxifen20,21. 
 
Data were analysed using SPSS v23 (IBM, Armonk, New York, USA). Normally distributed data are 
presented as mean and SD (age, body fat percentage, waist, total, LDL and HDL cholesterol, glucose, 
fibre and saturated fat), otherwise median and range are presented. Categorical data are presented 
as number and percentage (deprivation, smoking, proportion not meeting recommendations for BMI, 
body fat percentage, waist, lipids, glucose, PA and dietary variables). Independent samples t-tests, 
Mann-Whitney U tests and Pearson’s chi squared tests were used to compare the Tam-Prev and HSE 
populations at baseline. Changes over one year were calculated for weight, BMI, body fat, waist, PA 
and the dietary variables using both per protocol and baseline observation carried forward (BOCF) 
values. Normally distributed change variables (weight, BMI, body fat, waist, PA and saturated fat) were 
compared using paired samples t-tests, otherwise related samples Wilcoxon signed-rank tests were 
used.  
 
Results 
 
Baseline characteristics  
Baseline characteristics of Tam-Prev participants are reported in Table 1. At the time of joining, 
participants had been under the care of the FHC for a median of four (range 0-19) years and none 
were known BRCA gene mutation carriers. The Tam-Prev population was marginally older than the 
HSE population but had an equivalent spread of deprivation. Women in Tam-Prev were slightly taller 
(mean [SD] 1.65 [0.06] vs 1.63 [0.06] cm, p<0.001), however median BMIs of the populations were 
comparable (median [range] 25.9 [18.4-50.8] kg/m2 Tam-Prev and 25.8 [15.71-58.44] kg/m2 HSE, 
p=803) because the Tam-Prev population were non-significantly heavier than the HSE population 
(median [range] 70 (45.5-130.2) vs 68.5 (37.5-140.4), p=0.106). The majority of women in both 
populations were either overweight or obese (59.2 and 55.3% in Tam-Prev and HSE). This aligns with 
the observation that half of women in Tam-Prev had a body fat percentage above the normal range22. 
The mean waist measurement of women in Tam-Prev was significantly greater than the general 
population (90.4 [16.0] vs 86.1 [12.7] cm, p=0.001). This is likely to be due to different measurement 
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techniques used in the two studies and not the small height difference. Mean total cholesterol level 
was lower in the Tam-Prev population compared to the general population (4.9 [0.8] vs 5.2 [1.0] 
mmol/L, p<0.001), however the HDL fraction was also lower (1.5 [0.3] vs 1.6 [0.4] mmol/L, p<0.001) 
and 26.7% of Tam-Prev women had a low HDL level (<1.29 mmol/L) compared to 17.6% of the HSE 
population (p=0.019), which is one of the markers of the metabolic syndrome23. Other markers of the 
metabolic syndrome were present in Tam-Prev women; 13.9% had triglycerides ≥1.7 mmol/L and 4.4% 
had fasting plasma glucose ≥5.6 mmol/L23. HOMA, a measure of insulin resistance which increases risk 
of metabolic syndrome, was increased (>2.5) in 14.1% of Tam-Prev women24. 
 
Table 1: Baseline characteristics of women in the Tam-Prev study compared to an age matched women 
in the general population in England  
  Tam-Prev 
population 
English population 1   P value 
Age (years) 2 41.2 (3.5) 
(n=136) 
39.7 (4.0) 
(n=1072) 
<0.001 
 
Indices of Deprivation 3 
1 (least deprived) 
2 
3 
4 
5 (most deprived) 
 
33 (24.3%) 
34 (25.0%) 
24 (17.6%) 
25 (18.4%) 
20 (14.7%) 
(n=136) 
 
234 (21.8%) 
209 (19.5%) 
217 (20.2%) 
210 (19.6%) 
202 (18.8%) 
(n=1072) 
 
0.439 
Height (m) 2 1.65 (0.06) 
(n=130) 
1.63 (0.06) 
(n=955) 
<0.001 
 
Weight (kg) 4 70 (45.5 – 130.2) 
(n=130) 
68.5 (37.5 – 140.4) 
(n=898) 
0.106 
BMI (kg/m2) 4 25.9 (18.4 – 50.8) 
(n=130) 
25.8 (15.71 – 58.44) 
(n=894) 
0.803 
BMI category  3, 5 
Underweight (<18.5 kg/m2) 
Normal (18.5 – 24.9 kg/m2) 
Overweight (25 – 29.9 kg/m2) 
Obese (≥30.0 kg/m2) 
 
1 (0.8%) 
52 (40.0%) 
46 (35.4%) 
31 (23.8%) 
(n=130) 
 
14 (1.6%) 
386 (43.2%) 
279 (31.2%) 
215 (24.0%) 
(n=894) 
0.709 
Body fat percentage (%) 6 
 
Body fat percentage over the ideal 
for their age 7  
34.2 (7.3) 
(n=130) 
50% 
No data 
 
No data 
 
- 
 
- 
 
Waist (cm) 2, 8 
 
90.4 (16.0) 
(n=131) 
86.1 (12.7) 
(n=659) 
0.001 
 
Total cholesterol (mmol/L) 2 4.9 (0.8) 
(n=135) 
5.2 (1.0) 
(n=488) 
<0.001 
LDL cholesterol (mmol/L) 6 3.0 (0.7) 
(n=135) 
No data - 
HDL cholesterol (mmol/L) 2 
 
1.5 (0.3) 
(n=135) 
1.6 (0.4) 
(n=488) 
<0.001 
 
5 
 
HDL cholesterol <1.29 mmol/L 3, 9 26.7% 17.6% 0.019 
Triglycerides (mmol/L) 10 
 
Triglyceride level ≥1.7 mmol/L 9  
0.8 (0.3 – 3.1) 
(n=136) 
13.9% 
No data 
 
- 
 
Glucose (mmol/L) 6 
 
Glucose ≥5.6 mmol/L 9 
4.7 (0.4) 
(n=136) 
4.4% 
No data 
 
- 
 
HOMA insulin resistance 10 
 
HOMA insulin resistance ≥2.5 11  
1.5 (0.4 – 6.1) 
(n=135) 
14.1% 
No data 
 
- 
 
1 (18), 2 Mean (SD) and independent samples t-test, 3 Percentage and Pearson’s chi squared, 4 Median 
(range) and Mann Whitney U test, 5 (52), 6 Mean (SD), 7 (22), 8 Waist for Tam-Prev population measured 
across umbilicus, HSE measured at the midpoint between the lower rib and the upper margin of the 
iliac crest, 9 (23), 10 Median (range), 11 (24) 
 
Table 2 compares health behaviours in the two populations. Smoking was less prevalent amongst the 
Tam-Prev women (10.5 vs 18.2%, p=0.032). A third of women in both populations did not meet PA 
guidelines. Median daily alcohol intake was markedly higher in Tam-Prev women (13.6 [0-107.8] vs 
3.6 [0-680.0] g per day, p<0.001) and 45% of Tam-Prev participants exceeded the recommended UK 
maximum of 14 units per week(equivalent to 1.4 bottles of wine or six pints of lager) compared to 
18.7% of the HSE population (p<0.001). Proportions of Tam-Prev women not meeting UK guidelines 
for fibre, saturated fat and NMES were 88%, 65% and 21% respectively, though there were no 
comparable figures for the HSE population. 
 
Table 2: Baseline health behaviours of women in the Tam-Prev study compared to an age matched 
women in the general population in England  
  Tam-Prev 
population 
English population 1  P value 
Smoker 2 10.5% 
(n=124) 
18.2% 
(n=1071) 
0.032 
Do not meet physical activity 
guidelines 2, 3 
(minimum 150 min/week moderate 
intensity or 75 min/week vigorous 
intensity physical activity or a 
combination)  
30.6% 
(n=134) 
35.1% 
(n=1059) 
0.229 
Alcohol intake (g per day) 4 
 
Exceed UK guidelines of ≤14 units per 
week 2 
(8g = 1 unit of alcohol) 
13.6 (0 – 107.8) 
 
45.0% 
(n=131) 
3.6 (0 – 680.0) 
 
18.7% 
(n=1049) 
<0.001 
 
<0.001 
Fibre (g per day) 5 
 
Do not meet UK daily 
recommendation of >24g/ day 6 
17.5 (5.3) 
 
87.8% 
No data 
 
- 
Saturated fat (g per day) 5 26.1 (10.3) No data - 
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Percentage of daily energy from 
saturated fat 5 
 
Exceed UK recommendation of <11% 
of energy 6 
 
12.4 (3.1) % 
 
 
64.9% 
 
 
Non-milk extrinsic sugar (g per day) 7 
 
Percentage of daily energy from non-
milk extrinsic sugars 5 
 
Exceed UK recommendation of <11% 
of energy 6 
37.2 (0.1 – 145.1) 
 
8.1 (4.6) % 
 
 
21.4% 
No data 
 
- 
1 (18), 2 Percentage and Pearson’s chi squared, 3 Physical activity data for Tam-Prev collected using IPAQ 
short version covering the previous seven days, HSE used a longer set of questions covering the 
previous four weeks, 4 Median (range) and Mann Whitney U test, 5 Mean (SD), 6 (53), 7 Median (range) 
 
Of 115 women in Tam-Prev with full information, over half (51%) had at least two out of four key 
lifestyle risk factors for BC as defined by the World Cancer Research Fund and the American Institute 
for Cancer Research (overweight or obesity, low PA, smoking, exceeding seven alcoholic drinks per 
week: 9-13 units / week), 18% had at least three, and one patient had all four. Only 8.7% had a low-
risk lifestyle with none of these risk factors25.  
 
Withdrawal from the Tam-Prev Study 
Twenty-seven women (19.9%) withdrew before one year: 21 (15.4%) due to tamoxifen side effects, 
three (2.2%) lost contact, one (0.7%) became pregnant and two (1.5%) left for other reasons. There 
were no differences in baseline BMI or smoking status between completers and those that dropped 
out (median BMI [range] 26.3 [18.4-45.7] vs 25.2 [19.5-50.8] kg/m2, p=0.943; 10.1 vs 13.3% smokers, 
p=0.701), however completers had a higher alcohol intake (15.6 [0.0-107.8] vs 4.0 [0.0-58.6] g/day, 
p=0.001). Three participants took tamoxifen for less than one year but their results are included here 
as they completed the one year assessments.  
 
Change after one year of chemoprevention 
Per-protocol analyses are reported in Table 3. BOCF analyses gave similar results (data not shown). 
There were modest reductions in weight, BMI and body fat mass over the year. Using ±3% to define 
natural daily weight variation26, 23% of women lost weight, 68% maintained, and 9% gained. The 
proportions losing and gaining a clinically significant 5% of baseline weight were 15.7% and 4.6% 
respectively27. Neither PA nor alcohol intake changed during the year.  
 
There were small reductions in saturated fat (26.1g to 24.0g per day, p=0.011) and NMES (37.2g to 
33.7g per day, p=0.030), but no change in other dietary parameters. Despite these reductions, 65.3% 
and 18.8% of women exceeded recommendations at one year for saturated fat and NMES intakes 
respectively. Significant proportions of the women remained overweight and were not adhering to 
recommendations for PA, alcohol or diet at one year. 
 
 
 
Table 3: Per-protocol analysis of change at one year 
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 Baseline 
(completers 
only, n=109) 
One year p value for 
change 
% not meeting UK 
recommendations 
at baseline 
% not meeting UK 
recommendations 
at one year 
Weight (kg) 1 
(n=108) 
74.8 (17.6) 73.8 (17.1) 0.001 - - 
BMI (kg/m2) 1 
(n=108) 
 
BMI category 
2 
Underweight 
(<18.5 kg/m2) 
Normal (18.5 
– 24.9 kg/m2) 
Overweight 
(25 – 29.9 
kg/m2) 
Obese (≥30.0 
kg/m2) 
27.2 (6.0) 
 
26.9 (5.9) 0.001  
 
 
 
 
0.9% 
 
39.8% 
 
35.2% 
 
 
24.1% 
 
 
 
 
 
 
0.9% 
 
43.5% 
 
31.5% 
 
 
24.1% 
Body fat (kg) 1 
(n=108) 
26.6 (11.7) 
 
26.0 (11.6) 0.010 - - 
Waist (cm) 1 
(n=108) 
 
Waist >80cm 3 
90.1 (15.3) 
 
90.5 (14.8) 0.556  
 
 
68.8% 
 
 
 
74.1% 
Physical 
activity 
(Metabolic 
Equivalent of 
Tasks [MET]- 
minutes / 
week) 1 
(n=109) 
3249 (2750) 3054 (2473) 0.719 30.3% 27.6% 
Alcohol (g per 
day) 3 
(n=101) 
15.6 (0.0 – 
107.8) 
 
15.8 (0 – 
91.3) 
0.496 49.5% 50.5% 
Fibre (g per 
day) 3 
(n=101) 
17.9 (7.0 – 
34.8) 
 
16.8 (0.9 – 
41.2) 
0.085 84.2% 92.3% 
Saturated fat 
(g per day) 1 
(n=101) 
26.1 (10.2) 
 
24.0 (8.4) 0.011 61.4% 65.3% 
Non-milk 
extrinsic 
sugar (g per 
day) 3 (n=101) 
37.2 
(0.1 – 145.1) 
33.7 (1.9 – 
195.7) 
0.030 20.8% 18.8% 
1 Mean (SD) for values at baseline and one year, paired samples t-test for change, 2 (52), 3 (23,54), 3 Median 
(range) for values at baseline and one year, related samples Wilcoxon signed rank test for change 
 
Discussion 
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Here we report lifestyle behaviours and health measures in women in an FHC taking tamoxifen for 
prevention of BC, and the change in these during a year of chemoprevention. At baseline, Tam-Prev 
participants had a high prevalence of unhealthy lifestyle behaviours, for example overweight, larger 
waist, low PA and adverse health measures, which were similar to an English, age-matched female 
population from the HSE. They also had higher alcohol intake but lower smoking rates. Significant 
proportions were found to have markers of poor metabolic health and indicators of poor diet.  
  
Previous studies of lifestyle behaviours in women at increased risk of BC in the UK have also found a 
high prevalence of overweight and obesity and low adherence to PA recommendations28,29.  Begum et 
al reported the majority of women (76%) in an English FHC were overweight or obese, 24% did no PA 
and 78% did less than four hours PA per week28, while Anderson et al found 52% of respondents in a 
Scottish genetics service were overweight or obese and 55% did not adhere to PA recommendations29. 
Both studies used self-reported methods for PA which are acknowledged to overestimate30 so it is 
likely that actual PA levels were even lower than reported.  
 
The lower rate of smoking in Tam-Prev (10.5%) compared to the general population (18.2%) is an 
interesting observation. Rouleau et al also found a lower prevalence of smoking in a population of 
women from Quebec with a family history of breast and/or ovarian cancer undergoing genetic 
testing31. Two UK surveys found many women with a family history of BC believe that smoking is one 
of the key risk factors28,29 rather than weight and lack of PA which have a greater impact on risk32. The 
low rates of smoking (around 10%) seen in the surveys could be due to these beliefs. 
 
We reported 45% of the Tam-Prev population exceeded alcohol recommendations. Similarly, the 
majority of women (56%) in a Scottish genetics service exceeded recommendations29, however only 
1% did in a survey of women in an English FHC28 despite intakes being self-reported in both studies. 
The apparent greater alcohol intake in the Tam-Prev than HSE populations could be the result of a 
difference in methods; HSE used a verbal food frequency questionnaire and Tam-Prev used a seven 
day food diary which may provide a more honest and accurate reflection of behaviours.  
 
Women in Tam-Prev, who all had a family history of BC, had a greater mean waist circumference 
compared with the general population which concurs with previous research33,34. However the 
difference reported here may be because the Tam-Prev study measured waist at the umbilicus which 
gives larger readings than the midpoint between the lower rib and the upper margin of the iliac crest 
as used in the HSE35.  
 
Women about to commence tamoxifen had lower levels of total and HDL cholesterol than women in 
the general population. Two studies by Boyd et al reported generally more favourable lipid profiles in 
women with a family history of BC, but findings were variable and the reasons for these potential 
differences are not understood36,37. Women with a family history of BC are reported to underestimate 
their CVD risk and overestimate their BC risk38. Our results suggest that a significant proportion of 
Tam-Prev women had an increased risk of CVD at baseline. Despite tamoxifen provoking beneficial 
reductions in total and LDL-cholesterol levels, it does not consistently lead to lower CVD rates, perhaps 
due to detrimental effects on triglyceride levels20 and insulin sensitivity21.  
 
Unhealthy behaviours amongst women with a family history of BC are not confined to the UK. A study 
of female BRCA mutation carriers in The Netherlands reported 40.7% overweight or obese, 27.0% 
current smokers, 47.5% physically inactive and 3.4% drank eight or more alcoholic beverages per 
week. Of those with complete lifestyle data, 32.1% had a low-risk lifestyle for BC (healthy weight, 
achieved PA recommendations, non-smokers, consumed seven alcoholic drinks or fewer per week) 
compared to just 8.7% in Tam-Prev25,39. Bostean et al reported that compared to Californian women 
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with no family history of cancer, women with a family history did not have better overall lifestyle 
behaviours scores, which included BMI, diet and PA40.  
 
Tam-Prev participants did not receive lifestyle advice, however they completed food diaries at 
baseline and one year which are known to promote behaviour change41 and could have contributed 
to the small improvements in weight and diet seen here. Sixteen percent of women achieved a 
clinically significant 5% weight loss. Our results agree with previous research showing that tamoxifen 
does not cause weight gain in the prevention setting42.  
 
The National Institute for Health and Care Excellence (NICE) recommend that women with a family 
history of BC in the UK receive written information on lifestyle, including diet, PA and alcohol43 
however patient surveys suggest this is not commonplace 29.  
 
Studies have found minimal or no change in lifestyle after BRCA counselling44–46. This is supported by 
a recent meta-analysis which found that disease risk information, even when personalised, does not 
have a strong effect on behaviour47. Belief in the efficacy of certain health behaviours to prevent or 
delay cancer has been associated with practice of these behaviours44. Therefore efforts to encourage 
behaviour change in FHCs should include education to address current poor understanding and 
improve credibility of lifestyle risk factors, and their response efficacy. This should be combined with 
an intervention proven to aid behaviour change such as a self-monitoring website with additional 
telephone calls48,49. 
 
This is the first prospective study on lifestyle behaviours and health measures in women undertaking 
BC chemoprevention. It benefits from an almost complete data set for women who entered Tam-Prev. 
Weaknesses include the comparison of the Tam-Prev population to the general English population in 
the HSE. We do not have data on women in our regional FHC who opt not to take tamoxifen, therefore 
cannot assess differences in lifestyle risks. The absence of a control group means we are unable to 
assess whether the changes observed differ in populations not on chemoprevention. Dietary and PA 
data were self-reported and people tend to underestimate amounts eaten and overestimate PA30,50,51. 
It is recognised that this could affect both data sets, though a strength is that both studies used self-
reported measures. 
 
The prevalence of suboptimal lifestyle behaviours amongst high risk women taking chemoprevention 
supports the need to embed lifestyle change in FHCs. Future research should focus on engaging high 
risk women with lifestyle improvement. This should reduce the burden of BC and other lifestyle-
related diseases, leading to potential improvements in quality of life, and cost savings for the NHS. 
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